TY  - JOUR
AU  - Faivre-Finn, Corinne
AU  - Vicente, David
AU  - Kurata, Takayasu
AU  - Planchard, David
AU  - Paz-Ares, Luis
AU  - Vansteenkiste, Johan F
AU  - Spigel, David R
AU  - Garassino, Marina C
AU  - Reck, Martin
AU  - Senan, Suresh
AU  - Naidoo, Jarushka
AU  - Rimner, Andreas
AU  - Wu, Yi-Long
AU  - Gray, Jhanelle E
AU  - Özgüroğlu, Mustafa
AU  - Lee, Ki H
AU  - Cho, Byoung C
AU  - Kato, Terufumi
AU  - de Wit, Maike
AU  - Newton, Michael
AU  - Wang, Lu
AU  - Thiyagarajah, Piruntha
AU  - Antonia, Scott J
PY  - 2021
DO  - 10.1016/j.jtho.2020.12.015
UR  - http://hdl.handle.net/10668/17007
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end...
LA  - en
KW  - Durvalumab
KW  - Locally advanced NSCLC
KW  - Overall survival
KW  - PACIFIC
KW  - Progression-free survival
KW  - Antibodies, Monoclonal
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
KW  - Humans
KW  - Lung Neoplasms
TI  - Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
TY  - research article
VL  - 16
ER  -